Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Debio 1347 in advanced solid tumors with FGFR fusions
NCT03834220Phase 2Terminated
- Sponsor
- Debiopharm
- Start
- Mar 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 2, open-label trial of zoligratinib in solid tumor, biliary tract cancer (BTC) and urothelial carcinoma (UC) (3 arms), sponsored by Debiopharm. Primary endpoint: Objective Response Rate. Started Mar 2019; status: terminated.
02
Drugs
zoligratinib
03
Conditions
solid tumorbiliary tract cancer (BTC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03834220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03834220.